Combination of Temozolomide and Sunitinib in Treatment of Patients With Metastatic and Unresectable Malignant Melanoma

  • participants needed
  • sponsor
    University of California, Los Angeles
Updated on 7 November 2020
advanced melanoma


The purpose of this study is to determine the safety and efficacy of the treatment with a combination of chemotherapy drug, temozolomide with a drug-blocking blood vessel formation, sunitinib malate in patients with advanced melanoma..


The therapy with a combination of a chemotherapeutic agent with a known activity against melanoma (temozolomide) and a new small molecule that inhibits angiogenesis (sunitinib malate) will be tested in this clinical trial. Both agents have been approved for use in humans with different types of malignancies, and the tolerated doses of each medication have been established,but they have never been studied in combination. Therefore, this trial will start as a phase-1 trial that will allow us to establish the maximum tolerated dose of both medications, and then we will proceed with the phase-2 trial. Temozolomide has been widely used in patients with melanoma, and protracted dosing of the drug has been shown to be safe; sunitinib malate has not been studied in melanoma. We will use temozolomide at a dose of 75mg/m2 daily, and only the dose of sunitinib malate will be escalated. The patient will be started on 12.5 mg of sunitinib malate daily. Both drugs will be given daily for 6 weeks out of an 8-week cycle. If no dose limiting toxicities are noted, the dose of sunitinib malate will be increased to 25 mg daily, and then to 37.5 mg daily.

Condition Melanoma
Treatment Temozolomide, Sunitinib
Clinical Study IdentifierNCT00859326
SponsorUniversity of California, Los Angeles
Last Modified on7 November 2020


How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note